Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-label, Multicenter, Initially Single-armed and in Case of Treatment Failure Subsequently Three-armed Randomized Clinical Trial of Phase III/IV Investigating the Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)

NCT04814511 is registered in ClinicalTrials.gov with Infectopharm Arzneimittel GmbH as lead sponsor.

NCT NCT04814511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04814511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-label, Multicenter, Initially Single-armed and in Case of Treatment Failure Subsequently Three-armed Randomized Clinical Trial of Phase III/IV Investigating the Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
Lead sponsor
Infectopharm Arzneimittel GmbH
Phase
Phase 3
Overall status
Unknown status
Start date
June 11, 2021
Completion date
August 31, 2023
Enrollment
183 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

scabies